EYSUVIS Drug Patent Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Which patents cover Eysuvis, and what generic alternatives are available?
Eysuvis is a drug marketed by Kala Pharms Inc and is included in one NDA. There are thirteen patents protecting this drug.
This drug has seventy-nine patent family members in twelve countries.
The generic ingredient in EYSUVIS is loteprednol etabonate. There are ten drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the loteprednol etabonate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Eysuvis
A generic version of EYSUVIS was approved as loteprednol etabonate by AKORN on April 17th, 2019.
Summary for EYSUVIS
International Patents: | 79 |
US Patents: | 13 |
Applicants: | 1 |
NDAs: | 1 |
Clinical Trials: | 1 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for EYSUVIS |
What excipients (inactive ingredients) are in EYSUVIS? | EYSUVIS excipients list |
DailyMed Link: | EYSUVIS at DailyMed |


Recent Clinical Trials for EYSUVIS
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Kala Pharmaceuticals, Inc. | Phase 4 |
Price Vision Group | Phase 4 |
Anatomical Therapeutic Chemical (ATC) Classes for EYSUVIS
US Patents and Regulatory Information for EYSUVIS
EYSUVIS is protected by thirteen US patents and one FDA Regulatory Exclusivity.
Patents protecting EYSUVIS
Nanocrystals, compositions, and methods that aid particle transport in mucus
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: A METHOD FOR DELIVERING A PHARMACEUTICAL AGENT ACROSS A MUCOSAL BARRIER
Compositions and methods for ophthalmic and/or other applications
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Compositions and methods for ophthalmic and/or other applications
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Compositions and methods for ophthalmic and/or other applications
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: A METHOD FOR TREATING DRY EYE IN A PATIENT
Compositions and methods for ophthalmic and/or other applications
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: A METHOD FOR TREATING DRY EYE IN A PATIENT
Compositions and methods for ophthalmic and/or other applications
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: A METHOD FOR TREATING DRY EYE IN A PATIENT
Compositions and methods for ophthalmic and/or other applications
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: ADMINISTRATION TO THE EYE OF A PATIENT FOR TREATMENT OF DRY EYE CONDITION
Compositions and methods for ophthalmic and/or other applications
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: A METHOD FOR TREATING DRY EYE IN A PATIENT
Nanocrystals, compositions, and methods that aid particle transport in mucus
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: A METHOD FOR DELIVERING A COMPOSITION TO A MUCUS MEMBRANE
Nanocrystals, compositions, and methods that aid particle transport in mucus
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Nanocrystals, compositions, and methods that aid particle transport in mucus
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: A METHOD FOR DELIVERING A COMPOSITION TO A MUCUS MEMBRANE
Nanocrystals, compositions, and methods that aid particle transport in mucus
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: A METHOD FOR DELIVERING A PHARMACEUTICAL AGENT ACROSS A MUCOSAL BARRIER
Compositions and methods for ophthalmic and/or other applications
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: A METHOD FOR TREATING DRY EYE IN A PATIENT
FDA Regulatory Exclusivity protecting EYSUVIS
NEW PRODUCT
Exclusivity Expiration: See Plans and Pricing
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Kala Pharms Inc | EYSUVIS | loteprednol etabonate | SUSPENSION/DROPS;OPHTHALMIC | 210933-001 | Oct 26, 2020 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | |||
Kala Pharms Inc | EYSUVIS | loteprednol etabonate | SUSPENSION/DROPS;OPHTHALMIC | 210933-001 | Oct 26, 2020 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | |||
Kala Pharms Inc | EYSUVIS | loteprednol etabonate | SUSPENSION/DROPS;OPHTHALMIC | 210933-001 | Oct 26, 2020 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for EYSUVIS
See the table below for patents covering EYSUVIS around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Japan | 6816064 | See Plans and Pricing | |
South Korea | 20150006869 | PHARMACEUTICAL NANOPARTICLES SHOWING IMPROVED MUCOSAL TRANSPORT | See Plans and Pricing |
South Korea | 20210013339 | PHARMACEUTICAL NANOPARTICLES SHOWING IMPROVED MUCOSAL TRANSPORT | See Plans and Pricing |
>Country | >Patent Number | >Title | >Estimated Expiration |